Edwards Lifesciences Corporation (EW) – What Are Researchers Saying About This Stock?

Edwards Lifesciences Corporation (NYSE:EW) has received a consensus recommendation of “Moderate Buy” from the twenty-six ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $109.56.

A number of equities analysts have commented on the company. Jefferies Financial Group lifted their price target on Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Wells Fargo & Company reissued an “overweight” rating and set a $113.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, November 5th. Argus increased their price objective on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Finally, UBS Group lifted their target price on shares of Edwards Lifesciences from $110.00 to $118.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th.

Insider Activity

In related news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $104.25, for a total value of $64,530.75. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $4,173,544.50. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 53,945 shares of company stock valued at $5,498,306. 0.31% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Legacy Trust raised its position in Edwards Lifesciences by 1.4% in the third quarter. Legacy Trust now owns 7,409 shares of the medical research company’s stock worth $682,000 after purchasing an additional 104 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Edwards Lifesciences by 0.4% during the third quarter. Bessemer Group Inc. now owns 28,358 shares of the medical research company’s stock valued at $2,447,000 after purchasing an additional 114 shares in the last quarter. Harbour Wealth Management Group Inc. boosted its holdings in Edwards Lifesciences by 3.9% during the third quarter. Harbour Wealth Management Group Inc. now owns 3,070 shares of the medical research company’s stock valued at $265,000 after purchasing an additional 114 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of Edwards Lifesciences by 1.2% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock valued at $916,000 after purchasing an additional 125 shares during the period. Finally, Fifth Third Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 1.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 132 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.3%

Shares of EW traded up $1.36 during trading hours on Friday, hitting $107.16. The company had a trading volume of 3,822,134 shares, compared to its average volume of 4,833,862. The firm has a market cap of $61.62 billion, a P/E ratio of 60.54, a P/E/G ratio of 2.82 and a beta of 0.85. The stock’s 50 day moving average price is $90.42 and its 200 day moving average price is $86.32. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $107.69.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. Edwards Lifesciences’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. On average, research analysts predict that Edwards Lifesciences will post 3.01 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.